A Polymorphism in the PDLIM5 Gene Associated with Gene Expression and Schizophrenia
Department of Medical Genetics, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan. Biological Psychiatry
(Impact Factor: 10.26).
04/2006; 59(5):434-9. DOI: 10.1016/j.biopsych.2005.07.041
Results of recent DNA microarray analyses of postmortem brains of patients with schizophrenia revealed that expression of the PDZ and LIM domain 5 gene (PDLIM5) is increased. In the present study, we examined whether polymorphisms in PDLIM5 are associated with schizophrenia.
We screened for mutations in PDLIM5 in 24 Japanese patients with schizophrenia and evaluated the associations of the identified polymorphisms with schizophrenia in a Japanese case-control population (total samples, 278 schizophrenia patients and 462 control subjects). Expression of PDLIM5 was quantified by real-time quantitative polymerase chain reaction (PCR) in postmortem prefrontal cortex of 34 schizophrenia patients. Electrophoretic mobility shift assay (EMSA) was performed to examine whether a polymorphism influences nuclear protein binding.
We identified 27 polymorphisms in PDLIM5 and found associations between polymorphisms (rs2433320 and rs2433322) in the 5' region of the gene and schizophrenia (p = .004). Real-time quantitative PCR revealed that these polymorphisms influenced gene expression (p = .007). An EMSA showed that the different alleles of the rs2433320 polymorphism bound differently to nuclear proteins.
These results suggest that PDLIM5 might play a role in genetic susceptibility to schizophrenia.
Available from: Tadao Arinami
- "Recent studies have shown that SNPs in the PDLIM5 gene are associated with schizophrenia , , , bipolar disorder , , , and major depression , . In contrast, other studies have reported no significant genetic association between the PDLIM5 gene and schizophrenia , . "
[Show abstract] [Hide abstract]
ABSTRACT: Reports indicate that PDLIM5 is involved in mood disorders. The PDLIM5 (PDZ and LIM domain 5) gene has been genetically associated with mood disorders; it's expression is upregulated in the postmortem brains of patients with bipolar disorder and downregulated in the peripheral lymphocytes of patients with major depression. Acute and chronic methamphetamine (METH) administration may model mania and the evolution of mania into psychotic mania or schizophrenia-like behavioral changes, respectively.
To address whether the downregulation of PDLIM5 protects against manic symptoms and cause susceptibility to depressive symptoms, we evaluated the effects of reduced Pdlim5 levels on acute and chronic METH-induced locomotor hyperactivity, prepulse inhibition, and forced swimming by using Pdlim5 hetero knockout (KO) mice.
The homozygous KO of Pdlim5 is embryonic lethal. The effects of METH administration on locomotor hyperactivity and the impairment of prepulse inhibition were lower in Pdlim5 hetero KO mice than in wild-type mice. The transient inhibition of PDLIM5 (achieved by blocking the translocation of protein kinase C epsilon before the METH challenge) had a similar effect on behavior. Pdlim5 hetero KO mice showed increased immobility time in the forced swimming test, which was diminished after the chronic administration of imipramine. Chronic METH treatment increased, whereas chronic haloperidol treatment decreased, Pdlim5 mRNA levels in the prefrontal cortex. Imipramine increased Pdlim5 mRNA levels in the hippocampus.
These findings are partially compatible with reported observations in humans, indicating that PDLIM5 is involved in psychiatric disorders, including mood disorders.
PLoS ONE 04/2013; 8(4):e59320. DOI:10.1371/journal.pone.0059320 · 3.23 Impact Factor
Available from: Zahurin Mohamed
- "In genetic association studies, single nucleotide polymorphisms (SNPs) that are located in the upstream region of PDLIM5 have been found to be associated with BPD [6,7], schizophrenia , and major depressive disorder . In addition, previous studies showed a significant association between BPD and haplotypes of PDLIM5 polymorphisms located in the upstream region [7,10]. "
[Show abstract] [Hide abstract]
One of the genes suggested to play an important role in the pathophysiology of bipolar disorder (BPD) is PDLIM5, which encodes LIM domain protein. Our main objective was to examine the effect of olanzapine treatment on PDLIM5 mRNA expression in the peripheral blood leukocytes of BPD patients.
We measured the expression of PDLIM5 mRNA from 16 patients with BPD Type I after 0, 4, and 8 weeks of treatment with olanzapine using quantitative real-time PCR. The Young Mania Rating Scale was used to evaluate the severity of manic symptoms in BPD patients. We also compared PDLIM5 mRNA expression in treatment-naïve BPD patients with that in healthy control subjects.
No significant difference was found in PDLIM5 mRNA expression between patients before olanzapine treatment and following 4 and 8 weeks of treatment (p>0.05). Although we observed a significant reduction in the severity of manic symptoms in all BPD patients (p<0.05), the effectiveness of the medication did not significantly correlate with the expression of PDLIM5 mRNA (p>0.05). Interestingly, PDLIM5 mRNA expression differed significantly between treatment-naïve BPD patients and healthy control subjects (p=0.002).
PDLIM5 mRNA expression did not appear to be a reflection of the efficacy of olanzapine in reducing the manic symptoms of BPD. The significant difference in expression of PDLIM5 mRNA in the peripheral blood leukocytes of treatment-naïve BPD patients versus that of healthy control subjects, however, suggests that it may be a good biological marker for BPD.
BMC Medical Genetics 10/2012; 13(1):91. DOI:10.1186/1471-2350-13-91 · 2.08 Impact Factor
Available from: Scott Herrick
- "Furthermore, single nucleotide polymorphisms (SNPs) in PDLIM5 have been linked to schizophrenia (Horiuchi et al., 2006; Li et al., 2008), major depressive disorder (Liu et al., 2008), and bipolar disorder (Kato et al., 2005), suggesting that PDLIM5 may be a general susceptibility gene for psychiatric illnesses. Certain SNPs located within the 5′ untranslated region of PDLIM5 are associated with increased levels of PDLIM5 expression (Horiuchi et al., 2006), and mRNA levels of PDLIM5 have been found to be elevated in post-mortem brains of patients with schizophrenia, bipolar disorder, and major depression (Iwamoto et al., 2004a; Iwamoto et al., 2004b; Kato et al., 2005). Mimicking this upregulation by overexpressing PDLIM5 in cultured hippocampal neurons resulted in excessively thin dendritic spines. "
[Show abstract] [Hide abstract]
ABSTRACT: Dendritic spine morphology is thought to play important roles in synaptic development and plasticity, and morphological derangements in spines are correlated with several neurological disorders. Here, we identified an interaction between Spine-Associated RapGAP (SPAR), a postsynaptic protein that reorganizes actin cytoskeleton and drives dendritic spine head growth, and PDLIM5/Enigma Homolog (ENH), a PDZ-LIM (postsynaptic density-95/Discs large/zona occludens 1-Lin11/Isl-1/Mec3) family member. PDLIM5 has been implicated in susceptibility to bipolar disorder, major depression, and schizophrenia, but its function in neurological disease is poorly understood. We show that PDLIM5 is present in the postsynaptic density, where it promotes decreased dendritic spine head size and longer, filopodia-like morphology. Conversely, RNA interference against PDLIM5 or loss of PDLIM5 interaction with SPAR caused increased spine head diameter. Furthermore, PKC activation promoted delivery of PDLIM5 into dendritic spines and increased its spine colocalization with SPAR. These data reveal new postsynaptic functions for PDLIM5 in shrinkage of dendritic spines that may be relevant to its association with psychiatric illness.
Molecular and Cellular Neuroscience 11/2009; 43(2):188-200. DOI:10.1016/j.mcn.2009.10.009 · 3.84 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.